Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the hematological remission, defined as CR (both CR and CRi), as reported by the external independent endpoint adjudication committee, in patients with relapsed/refractory ALL randomized to receive inotuzumab ozogamicin (Arm A) versus patients randomized to receive active comparator (Arm B).
Critère d'inclusion
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia